A Protein Phosphatase Methylesterase (PME-1) Is One of Several Novel Proteins Stably Associating with Two Inactive Mutants of Protein Phosphatase 2A*

Abstract

Carboxymethylation of proteins is a highly conserved means of regulation in eukaryotic cells. The protein phosphatase 2A (PP2A) catalytic (C) subunit is reversibly methylated at its carboxyl terminus by specific methyltransferase and methylesterase enzymes which have been purified, but not cloned. Carboxymethylation affects PP2A activity and varies during the cell cycle. Here, we report that substitution of glutamine for either of two putative active site histidines in the PP2A C subunit results in inactivation of PP2A and formation of stable complexes between PP2A and several cellular proteins. One of these cellular proteins, herein named protein phosphatase methylesterase-1 (PME-1), was purified and microsequenced, and its cDNA was cloned. PME-1 is conserved from yeast to human and contains a motif found in lipases having a catalytic triad-activated serine as their active site nucleophile. Bacterially expressed PME-1 demethylated PP2A C subunit in vitro, and okadaic acid, a known inhibitor of the PP2A methylesterase, inhibited this reaction. To our knowledge, PME-1 represents the first mammalian protein methylesterase to be cloned. Several lines of evidence indicate that, although there appears to be a role for C subunit carboxyl-terminal amino acids in PME-1 binding, amino acids other than those at the extreme carboxyl terminus of the C subunit also play an important role in PME-1 binding to a catalytically inactive mutant.

Footnotes

  • * This work was supported in part by National Institutes of Health Grant CA57327 (to D. C. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Supported by an Erwin Schrödinger Postdoctoral Fellowship and Austrian Science Foundation Grant FWF, P12523-MOB.

  • Contributed equally to the results of this work.

  • Present address: Cubist Pharmaceuticals, Inc., Cambridge, MA 02139.

  • ¶¶ To whom correspondence should be addressed: Dept. of Biochemistry, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322. Tel.: 404-727-5620; Fax: 404-727-3231; E-mail:dpallas{at}emory.edu.

  • 2 L. Haehnel and D. C. Pallas, unpublished data.

  • 3 X. X. Yu, X. Du, E. Ogris, R. E. Green, Q. Feng, L. Clon, and David Pallas, submitted for publication.

  • 4 E. Ogris, I. Mudrak, E. Mak, D. Gibson, and D. C. Pallas, submitted for publication.

  • 5 D. C. Pallas, unpublished data.

  • 6 X. Du and D. C. Pallas, unpublished data.

  • 7 K. C. Nelson and D. C. Pallas, unpublished data.

  • Abbreviations:
    PP2A

    protein phosphatase 2A

    MT

    middle tumor antigen

    ST

    small tumor antigen

    EST

    expressed sequence tag

    RT-PCR

    reverse transcriptase-polymerase chain reaction

    PAGE

    polyacrylamide gel electrophoresis

    UTR

    untranslated region

    wt

    wild type

    ORF

    open reading frame

    PMSF

    phenylmethylsulfonyl fluoride

    • Received October 14, 1998.
    • Revision received January 29, 1999.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement